In agreement with previous studies, we found that bilateral STZ injection in the lateral ventricles of brain caused memory impairment. Previous studies have shown that ICV STZ injections chronically decrease cerebral glucose uptake and produce multiple other effects that resemble molecular, pathological, and behavioral features of AD. Taking into consideration that glucose hypometabolism is an early and persistent sign of AD and that Alzheimer’s brains present features of impaired insulin signaling, ICV STZ injections are exploited by some investigators as a non-transgenic model of this disease and used for preclinical testing of pharmacological therapies for
